Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients? [Meeting Abstract]

Ozkan, MetinBozkurt, OktayHacibekiroglu, IlhanKaplan, Muhammet AliDuzkopru, YakupUysal, MukreminKaraca, Halit2024-06-122024-06-1220150732-183X1527-7755https://doi.org/10.1200/jco.2015.33.15_suppl.e15624https://hdl.handle.net/20.500.14551/25929Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL[Abstract Not Available]en10.1200/jco.2015.33.15_suppl.e15624info:eu-repo/semantics/closedAccess[No Keywords]Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients? [Meeting Abstract]Conference Object3315Q1WOS:000358036903163